Skip to main content
. 2017 Dec 7;8(70):115054–115067. doi: 10.18632/oncotarget.23014

Figure 1. Androgen-AR signaling suppresses YAP1 gene expression.

Figure 1

(A) The levels of YAP1 protein were measured by Western Blot in LNCaP and 22RV1 cells upon AR knockdown. (B) The levels of YAP1 protein were measured in LNCaP cells treated for 24 h with the AR antagonist MDV3100 (enzalutamide, 100 nM) and Casodex (Bicalutamide, 10mM). (C) Quantitation of the immunofluorescence staining of AR (red) and YAP1(green) in BHP, HNPC and CRPC tissue samples from prostate cancer patients. (D) qPCR measurements of AR, PSA, YAP1, ANKRD and CTGF mRNA expression in siAR transfected LNCaP cells. Statistical analysis used Student’s T-Test, (*p < 0.05,**p < 0.01). Error bars represent the SD of triplicate measurements. (E) YAP1 promotor driven luciferase activity in LNCaP cell transfected with an siRNA targeting the AR or treated with AR antagonist MDV3100. The signal was quantified and statistical significance analyzed by Student’s T-Test, (*p < 0.05,**p < 0.01). (F) The levels of YAP1 proteins were measured by Western Blot in LNCaP after MDV3100 and CHX treatments for the indicated times.